Frequently Asked Questions About Skincare Manufacturing

Share the product category, target market, preferred development route, formula or ingredient direction, packaging status, expected quantity per SKU, target timing, and any testing or document requirements. Reference products and open questions are also useful. Review the complete project requirements rather than waiting until every detail is final.

Yes. An early product idea can begin an initial route review when you explain the intended category, user, market, positioning, and any known formula or packaging preferences. It is not enough to confirm final feasibility, price, MOQ, or timing. Use the project-requirements guide to identify the next decisions.

Rixin works with B2B customers such as skincare brands, distributors, retailers, spas, and professional skincare businesses. New and established businesses may both discuss projects, but acceptance depends on product scope, quantity, technical feasibility, packaging, timing, and market requirements. Read more about Rixin’s manufacturing focus .

Private label generally starts from an available or more established formula direction with selected adjustments. Custom Formulation & OEM is intended for projects requiring deeper formula development, adaptation, technical review, or manufacturing preparation. Compare Private Label Skincare with Custom Formulation & OEM before choosing a route.

Selected adjustments can be reviewed, but the scale of the change matters. Changes to ingredients, texture, fragrance, preservation, processing, filling, or packaging can affect stability, compatibility, testing, performance, MOQ, and timing. A request may move from private label into custom development after technical review. See the private-label route .

A buyer-selected material can enter review when its exact identity, specification, supplied form, handling requirements, supplier documents, and intended use are available. Acceptance is not automatic. Rixin must consider supply, processing, formula compatibility, packaging, testing, claims, and target-market requirements. Review the formula-development process .

Current development categories include facial cleansers, toners and essences, facial serums, moisturizers, facial masks, body care, hair and scalp care, men’s skincare, and sunscreen development. Individual formats and customization options still require project review. Explore the current product categories for the correct detailed page.

Yes, an ingredient trend can begin a development discussion. The exact commercial material, INCI identity, supplied form, supplier specification, formula compatibility, evidence, packaging, claims, and destination market still need review. Popularity alone does not prove finished-product performance or allowable wording. Start with the ingredient-development directions .

An authorized reference product can communicate intended texture, absorption, fragrance, appearance, dispensing, packaging, or positioning. It should not be treated as a promise of exact duplication. The resulting formula, raw materials, performance, package, and claims may differ after feasibility and evidence review. See Formula Development for the benchmark-review boundary.

Samples can be compared through observable criteria such as appearance, odor, texture, spread, absorption, residue, finish, dispensing, and intended-use fit. These observations help define an accepted direction, but they do not establish shelf life, microbiological quality, compatibility, or claims. Review the full sampling and formula-approval process .

Not automatically. The selected material must work within the complete formula, process, package, evidence base, intended use, and destination-market requirements. Supplier data or ingredient research does not by itself prove a finished-product claim. Review ingredient directions and the project-specific quality, testing, and documentation boundaries .

Rixin’s MOQ starts from 2,000 pieces per product. This is a starting point, not one universal minimum for every formula batch, package component, printing process, decoration method, or assembled set. Final quantities must be reviewed against the exact project. See the complete MOQ and lead-time guidance .

Quantity should be stated per product or SKU for project review. Different formulas, sizes, packages, colors, decorations, or printed materials may create separate minimum layers even when the products belong to one collection. Do not assume one combined total applies to every variant. Review the MOQ structure .

Do not assume that different SKUs can be combined. Separate formulas, batch requirements, containers, components, decoration, printing, and assembly may each carry their own minimum. Kits can also include product, component, and assembly quantities. Rixin must review the planned SKU structure through the MOQ and lead-time page .

Yes. Stock components, customized components, color matching, moulds, printing, labels, cartons, decoration, and supplier production rules can each create separate minimums. A 2,000-piece product quantity does not automatically mean every package option is available at that level. Review packaging early alongside the MOQ requirements .

The typical production lead time is approximately 40 days after the formula, packaging, artwork, quantities, and order details are confirmed. It is not the full development or delivery timeline. Formula work, sampling, revisions, unresolved packaging, buyer approvals, international shipping, and customs clearance sit outside that production period. See MOQ and Lead Time .

The schedule can be affected by formula complexity, sample revisions, raw-material or component availability, packaging customization, moulds, printing, decoration, artwork changes, testing, documents, SKU count, approvals, and production readiness. These are planning dependencies rather than guaranteed delay events. Define them early through the project requirements and timing guidance .

Yes. Formula sampling takes place before final production confirmation and may initially use neutral or temporary containers. The sample helps review the formula direction, but it does not automatically confirm final packaging, testing, claims, or production release. Sample fees, quantities, timing, and revision terms must be confirmed separately. Review sampling and formula approval .

Review appearance, odor, texture, spread, absorption, finish, residue, dispensing, and fit with the intended use. Record feedback against the exact sample version rather than using broad descriptions such as “lighter” or “better.” Sensory approval does not replace stability, microbiological, compatibility, or claim review. Use the sample-evaluation guidance .

No. Formula approval establishes an accepted formula and sample direction; it does not automatically approve the container, closure, dispenser, artwork, filling behavior, transport performance, compatibility, or production release. Final packaging can change formula exposure and dispensing. Review both formula approval and packaging capabilities .

Rixin can review available, customized, or buyer-nominated packaging routes and identify sourcing needs. Availability, supplier minimums, decoration, ownership, timing, filling, transport, and formula compatibility still require confirmation. Buyer-supplied components also need specifications and responsibility boundaries. Review the complete packaging and label-design capability .

No. Testing depends on the formula, package, intended use, claims, destination market, agreed scope, and responsibility split. An available test direction is not automatically included in every project. Methods, samples, acceptance criteria, timing, reports, and release rights must be confirmed. Review Quality, Testing & Documentation .

No. Rixin can support manufacturing review, testing direction, specifications, supplier files, and project documents within an agreed scope, but this does not replace qualified regulatory or legal review or the responsibilities required in the destination market. Market readiness must be defined by project. Review the documentation and responsibility boundaries .

The Certifications page presents ISO 22716 and Cosmetic GMP records for the holder, facility, manufacturing scope, certification body, and period stated on each document. Current status and continued-validity conditions must be verified against the active records. These are facility and system records, not approvals for every product. Review the current certification evidence .

No. FDA cosmetic facility registration is a facility registration, not a certification. It identifies a registered facility within the relevant system but does not certify its products, formulas, labels, claims, safety, efficacy, or compliance. Current registration status must be confirmed from the active record. Review the distinction on the Certifications page .

No. Facility registration does not mean that the FDA has approved, certified, endorsed, or evaluated a specific cosmetic product, formula, package, label, claim, or market launch. Product and labeling responsibilities remain separate from the facility record. Review the exact registration type and limitations on the Certifications page .

No. A facility certification applies only to the holder, location, scope, standard, period, and conditions stated on the record. It does not automatically approve every formula, finished product, package, label, claim, safety conclusion, retailer requirement, or market launch. Match each record to the project through the certification evidence .